Wednesday, July 8, 2026

Drug profile · INN

collagenase clostridium histolyticum

collagenase clostridium histolyticum (XIAPEX) is a collagen hydrolytic enzyme. Route of administration: injection. Current US regulatory status: approved.

FDA: approved EMA: withdrawn Musculo-skeletal system (M09) M09AB02
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — collagenase clostridium histolyticum
US status
approved
Class
Musculo-skeletal system (M09)
Route
INJECTION
Patents
0
Programs
0
Data quality
0.84

Quick answer

collagenase clostridium histolyticum (XIAPEX) is a collagen hydrolytic enzyme. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN collagenase clostridium histolyticum
Brand XIAPEX
Mechanism Collagen hydrolytic enzyme
Target Collagen
Therapeutic class Musculo-skeletal system (M09)
Route INJECTION
Formulation SOLUTION
ATC code M09AB02

Mechanism of action

Collagen hydrolytic enzyme

Primary target: Collagen

Approval history

Authority Status Date
FDA approved
EMA withdrawn

Related & competitor drugs

  1. allopurinol Musculo-skeletal system (M04)
  2. beremagene geperpavec Dermatologicals (D03)
  3. colchicine Musculo-skeletal system (M04)
  4. denosumab Musculo-skeletal system (M05)
  5. eteplirsen Musculo-skeletal system (M09)
  6. febuxostat Musculo-skeletal system (M04)

Frequently asked questions

What is collagenase clostridium histolyticum?

collagenase clostridium histolyticum (XIAPEX) is a collagen hydrolytic enzyme. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for collagenase clostridium histolyticum?

XIAPEX is a marketed brand name for collagenase clostridium histolyticum. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of collagenase clostridium histolyticum?

collagenase clostridium histolyticum has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.